Angiogenesis and Vascular Endothelial Growth Factor-A Expression Associated with Inflammation in Pediatric Crohn’s Disease

Journal of Gastrointestinal Surgery

Volumn 20, Issue 3, 2016, Pages 624-630

  Knod, J Leslie ^a   Crawford, Kelly ^a   Dusing, Mary ^a   Collins, Margaret H ^a   Chernoguz, Artur ^a   Frischer, Jason S ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Crohn s disease; Pediatric; VEGF A

Indexed keywords

ANGIOPOIETIN 1; ANGPT1 PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE; ANIMAL; CASE CONTROL STUDY; CHILD; CROHN DISEASE; FEMALE; HUMAN; ILEUM; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PRESCHOOL CHILD;

AGE FACTORS; ANGIOPOIETIN-1; ANIMALS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; ILEUM; MALE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84958110871     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-3002-1     Document Type: Article

References (49)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257.
3. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457–465.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974.
5. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066–2078.
6. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060–2073.
7. Pousa ID, Mate J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest 2008; 38: 73–81.
8. Chidlow JH, Jr., Langston W, Greer JJ, Ostanin D, Abdelbaqi M, Houghton J, Senthilkumar A, Shukla D, Mazar AP, Grisham MB, Kevil CG. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169: 2014–2030.
9. Danese S, Sans M, Spencer DM, Beck I, Donate F, Plunkett ML, de la Motte C, Redline R, Shaw DE, Levine AD, Mazar AP, Fiocchi C. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007; 56: 855–862.
10. Knod L, Donovan EC, Chernoguz A, Crawford KM, Dusing MR, Frischer JS. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis. J Surg Res 2013; 184: 101–107.
11. Chernoguz A, Crawford K, Vandersall A, Rao M, Willson T, Denson LA, Frischer JS. Pretreatment with anti-VEGF therapy may exacerbate inflammation in experimental acute colitis. J Pediatr Surg 2012; 47: 347–354.
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248.
13. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298–307.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
15. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
16. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822–828.
17. Scaldaferri F, Vetrano S, Sans M, Arena V, Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, Yla-Herttuala S, Fiocchi C, Danese S. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136: 585–595 e585.
18. Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A, Szabo S, Sandor Z. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328: 749–757.
19. Ardelean DS, Yin M, Jerkic M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis 2014; 17: 641–659.
20. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010; 16: 953–961.
21. Paul T, Birnbaum A, Pal DK, Pittman N, Ceballos C, LeLeiko NS, Benkov K. Distinct phenotype of early childhood inflammatory bowel disease. J Clin Gastroenterol 2006; 40: 583–586.
22. Polito JM, 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111: 580–586.
23. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114–1122.
24. Chidlow JH, Jr., Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293: G5-G18.
25. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Keough K, Fishman S. Elevated serum vascular endothelial growth factor in children and young adults with Crohn’s disease. Dig Dis Sci 1999; 44: 424–430.
26. Bousvaros A, Zurakowski D, Fishman SJ, Keough K, Law T, Sun C, Leichtner AM. Serum basic fibroblast growth factor in pediatric Crohn’s disease. Implications for wound healing. Dig Dis Sci 1997; 42: 378–386.
27. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262–267.
28. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653–660.
29. Spalinger J, Patriquin H, Miron MC, Marx G, Herzog D, Dubois J, Dubinsky M, Seidman EG. Doppler US in patients with Crohn’s disease: vessel density in the diseased bowel reflects disease activity. Radiology 2000; 217: 787–791.
30. D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014.
31. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G, Belgian Inflammatory Bowel Disease Research G, North-Holland Gut C. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138: 463–468; quiz e410-461.
32. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174–178.
33. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451–459.
34. Neumann H, Vieth M, Gunther C, Neufert C, Kiesslich R, Grauer M, Atreya R, Neurath MF. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis 2013; 19: 1935–1942.
35. Danese S, Fiorino G, Angelucci E, Vetrano S, Pagano N, Rando G, Spinelli A, Malesci A, Repici A. Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study. World J Gastroenterol 2010; 16: 2396–2400.
36. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007; 10: 149–166.
37. Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am J Pathol 2008; 172: 1457–1466.
38. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736–1743.
39. Tarnawski AS, Ahluwalia A. Molecular mechanisms of epithelial regeneration and neovascularization during healing of gastric and esophageal ulcers. Curr Med Chem 2012; 19: 16–27.
40. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000; 5: 40–46.
41. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.
42. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169–183.
43. Parvadia JK, Keswani SG, Vaikunth S, Maldonado AR, Marwan A, Stehr W, Erwin C, Uzvolgyi E, Warner BW, Yamano S, Taichman N, Crombleholme TM. Role of VEGF in small bowel adaptation after resection: the adaptive response is angiogenesis dependent. Am J Physiol Gastrointest Liver Physiol 2007; 293: G591-598.
44. Chidlow JH, Jr., Glawe JD, Pattillo CB, Pardue S, Zhang S, Kevil CG. VEGF(1)(6)(4) isoform specific regulation of T-cell-dependent experimental colitis in mice. Inflamm Bowel Dis 2011; 17: 1501–1512.
45. Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A, Danese S. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn’s disease. Am J Gastroenterol 2011; 106: 762–770.
46. Fishman SJ, Feins NR, RJ DA, Folkman J. Long-term remission of Crohn’s disease treated with thalidomide: a seminal case report. Angiogenesis 1999; 3: 201–204.
47. Boers-Sonderen MJ, Mulder SF, Nagtegaal ID, Jacobs JF, Wanten GJ, Hoentjen F, van Herpen CM. Severe exacerbation of Crohn’s disease during sunitinib treatment. Eur J Gastroenterol Hepatol 2014; 26: 234–236.
48. Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 2008; 19: 1975.
49. Coriat R, Mir O, Leblanc S, Ropert S, Brezault C, Chaussade S, Goldwasser F. Feasibility of anti-VEGF agent bevacizumab in patients with Crohn’s disease. Inflamm Bowel Dis 2011; 17: 1632.